Journal of Neuroinformatics and Neuroimaging

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Perspective - Journal of Neuroinformatics and Neuroimaging (2023) Volume 8, Issue 4

Impact of COVID-19 pandemic in the care of neuromuscular disease patients

Harroch Rein *

Department of Neuroscience, University of Padova, Padova, Italy

*Corresponding Author:
Harroch Rein
Department of Neuroscience
University of Padova
Padova, Italy

Received:27-Jul--2023, Manuscript No. AANN-23-109650; Editor assigned: 31-Jul-2023, PreQC No. AANN-23-109650 (PQ); Reviewed:14-Aug-2023, QC No. AANN-23-109650; Revised:21-Aug-2023, Manuscript No. AANN-23-109650(R); Published:28-Aug-2023, DOI: 10.35841/aann-8.4.157

Citation: Rein H. Impact of COVID-19 pandemic in the care of neuromuscular disease patients. J NeuroInform Neuroimaging. 2023;8(4):157

Visit for more related articles at Journal of Neuroinformatics and Neuroimaging




The COVID-19 pandemic has had an enormous impact on healthcare systems worldwide, particularly on the care of patients with neuromuscular diseases. These patients are often vulnerable to respiratory infections, and the pandemic has presented many challenges for their care, including disruption of medical appointments, reduced access to medications, and increased social isolation. Neuromuscular diseases are a group of disorders that affect the nerves and muscles, leading to weakness, muscle wasting, and functional impairment. These diseases include conditions such as muscular dystrophy, spinal muscular atrophy, myasthenia gravis, and amyotrophic lateral sclerosis (ALS). Many of these conditions are chronic and progressive, requiring ongoing medical care and monitoring [1].

The COVID-19 pandemic has significantly disrupted the care of neuromuscular disease patients. In many countries, non-urgent medical appointments and procedures have been postponed or canceled to reduce the risk of infection. This has meant that many patients have had to delay vital assessments, such as lung function tests, which are essential for monitoring disease progression and assessing the need for respiratory support. Patients with neuromuscular diseases may also require frequent hospitalizations for respiratory support or other complications. During the pandemic, hospitals have been overwhelmed with COVID-19 patients, resulting in reduced capacity and delays in accessing medical care. This has had a significant impact on the quality of life of patients with neuromuscular diseases, who may experience prolonged hospital stays or reduced access to necessary medical interventions [2].

The pandemic has also increased social isolation for many patients with neuromuscular diseases. Due to their underlying conditions, these patients may be at higher risk of severe illness or death from COVID-19. As a result, many have been advised to self-isolate, limiting their ability to engage in social activities and access support networks. This has had a significant impact on their mental health and well-being, leading to increased rates of depression and anxiety. Despite the challenges presented by the pandemic, there have also been some positive developments in the care of neuromuscular disease patients. Telemedicine has emerged as a vital tool for providing remote medical care and monitoring during the pandemic. Many healthcare providers have rapidly adopted telehealth services, allowing them to conduct virtual consultations and assessments with their patients. This has been particularly important for patients who are unable to attend in-person appointments due to COVID-19 restrictions [3].

The pandemic has also accelerated the development of new treatments and therapies for neuromuscular diseases. Researchers have been working to identify potential treatments for COVID-19, many of which may also have implications for the treatment of neuromuscular diseases. For example, studies have shown that the drug remdesivir, which was developed to treat COVID-19, may also be effective in treating spinal muscular atrophy. Additionally, the COVID-19 pandemic has underscored the need for comprehensive support systems for patients with neuromuscular diseases. Many of these individuals rely on a multidisciplinary approach to their care, involving not just medical professionals but also physical therapists, occupational therapists, and social workers. The pandemic has disrupted these support systems, making it more challenging for patients to access the comprehensive care they require. Physical therapy and rehabilitation play a crucial role in managing the symptoms and optimizing the quality of life for individuals with neuromuscular diseases [4].

However, lockdowns, social distancing measures, and the closure of rehabilitation centers and gyms have limited patients' ability to receive in-person therapy. This has necessitated the adoption of alternative approaches, such as virtual physical therapy sessions and home exercise programs. While these alternatives have provided some level of support, they may not fully replace the hands-on care and expertise that patients receive from in-person therapy. Furthermore, the pandemic has placed additional stress on caregivers of individuals with neuromuscular diseases. Many patients rely on the support and assistance of family members or professional caregivers for activities of daily living. The pandemic has increased the burden on caregivers, who have had to navigate increased safety precautions, isolation measures, and the added anxiety of potential exposure to the virus. The availability of respite care services, which provide temporary relief for caregivers, has been limited during the pandemic, further exacerbating the challenges they face [5].


The COVID-19 pandemic has had a significant impact on the care of neuromuscular disease patients. Disruptions to medical appointments, reduced access to medications, and increased social isolation have all presented challenges for these patients and their healthcare providers. However, the pandemic has also highlighted the importance of telemedicine and accelerated the development of new treatments and therapies. It is important that healthcare systems continue to adapt and innovate to meet the needs of these vulnerable patients during and beyond the pandemic.


  1. Anand P, Slama MC, Kaku M, et al COVID?19 in patients with myasthenia gravis . Muscle Nerve. 2020;62(2):254-8.
  2. Indexed at, Google Scholar, Cross Ref

  3. Camacho A, Esteban J, Paradas C. Report by the spanish foundation for the brain on the social impact of amyotrophic lateral sclerosis and other neuromuscular disorders . Neurología. 2018;33(1):35-46.
  4. Indexed at, Google Scholar, Cross Ref

  5. Paliwal VK, Garg RK, Gupta A, et al. Neuromuscular presentations in patients with COVID-19. Neurol Sci. 2020;41:3039-56.
  6. Indexed at, Google Scholar, Cross Ref

  7. Costello F, Dalakas MC. Cranial neuropathies and COVID-19: Neurotropism and autoimmunity.. Neurology. 2020;95:195-6.
  8. Indexed at, Google Scholar, Cross Ref

  9. Tankisi H, Tankisi A, Harbo T, et al. Critical illness myopathy as a consequence of COVID-19 infection.. Clin Neurophysiol. 2020;131:1931–32.
  10. Indexed at, Google Scholar, Cross Ref

Get the App